Product Images Losartan Potassium Tablets, 50 Mg

The text seems to be a table showing the adjusted risk reduction of patients with fatal and non-fatal stroke using Atenolol and Losartan Potassium. The percentage of risk reduction for the latter is 25% with a statistical significance of p=0.001. The table appears to show the study month and different percentages related to the risk reduction.*

This is a chart (Figure 3) displaying the primary endpoint events within different demographic subgroups. The primary composite stroke (fatal/non-fatal) rates for patients taking Losartan and Atenolol are compared. The chart is divided by age, gender, race, diabetes status, and history of CVD. The symbols on the chart are proportional to sample size. The chart also includes the hazard ratio (95% CI) for each subgroup. The text mentions that the data is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

This text is showing a comparison between two treatments, Losartan Potassium and Placebo. The table displays the percentage of patients with an event, with a risk reduction of 16.1%. The numbers 12, 24, and 48 are unclear.*

This is a description of a medication named Losartan. Losartan is a green oval-shaped tablet with the marking "C;334" on one side and "50 mg" on the other side. The medication's function includes containing 50mg of potassium. It is a generic version of Cozaar 50mg tablet and is manufactured and sold by Jubilant Cadista Pharma Inc. The medication should be stored at room temperature, preferably between 20°-25°C (68° T7°F). It is essential to keep all medications out of reach of children. The label shows that the medication comes with a 30 tablets package with an expiration date of MM/YY, and its NDC number is 7133518171 04238301523487.*